Donaldson purchases Solaris Biotechnology
Filtration products provider Donaldson has acquired bioprocessing equipment manufacturer Solaris Biotechnology for approximately 41 million euros ($45.9 million). Read More
Philogen, Janssen collaborate to discover small molecule therapeutics
Philogen and Janssen Biotech will collaborate to discover new small molecules of pharmaceutical interest using Philogen's lead-generation technologies. Specifically, Philogen and Janseen will work to identify small molecule compounds that bind to specific targets using Philogen's patented DNA-encoded chemical library technology platform. Read More
GreenLight Biosciences, Samsung Biologics collaborate on COVID-19 mRNA vaccine manufacturing
Samsung Biologics will collaborate with GreenLight Biologics to manufacture an mRNA COVID-19 vaccine candidate at a commercial scale. The partnership aims to accelerate production of GreenLight's COVID-19 vaccine candidate for phase III clinical trials, subject to regulatory approval. Read More
NIAID signs multimillion-dollar deal with ATCC
The U.S. National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health, awarded a seven-year contract valued at up to $545 million to ATCC to aid NIAID's research efforts in infectious and allergic diseases. Read More
Neurophth raises over $60M to advance gene therapies
Neurophth Therapeutics has raised over $60 million in series C financing to advance gene therapies for ophthalmic diseases. Read More
Red Cell forms Zephyr AI
Red Cell has formed Zephyr AI to transform drug discovery and precision medicine through the integration of artificial intelligence (AI). Read More
Stilla raises 31M euros in financing
Stilla Technologies has secured 31 million euros (about $35 million) in financing in the form of convertible bonds. The new funds will be used to further develop Stilla's global commercial presence and its next-generation digital polymerase chain reaction platform, the six-color Naica system, which it recently released. Read More
Merck licenses Dragonfly's immunotherapy for tumors
Merck has licensed its second trispecific NK (TrinKet) immunotherapy candidate from Dragonfly Therapeutics for solid tumors. Read More
Mission Bio touts study about its Tapestri platform
Mission Bio announced that its Tapestri platform helped elucidate resistance mechanisms to lung cancer drugs. Researchers from Memorial Sloan Kettering Cancer Center detail the discovery of these resistance mechanisms in a study that was published November 10 in Nature. Read More
Twist Bioscience to acquire Abveris for $190M
Twist Bioscience has entered into an agreement to purchase Abveris, a private in vivo antibody discovery firm, for $190 million. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter